FLII and acquired epidermolysis bullosa: These findings are in agreement with studies which demonstrated that reducing Flii expression, either genetically or using Flii neutralizing antibodies, decreased tissue inflammation, and disease severity in mouse models of psoriasiform dermatitis and epidermolysis bullosa acquisita (23, 24, 32).